|
|
|
|
||
another reason GLYC to pop much higher... I never root against competitor therapeutics and always sad when patients die in clinical trials - but article below drives home the need for effective, tolerable AML therapies... besides today's news from Magenta (MGTA) - 3 other biotechs failed AML trials in 2022. "In the quest for effective and innovative treatments for AML, several biopharma companies have recently hit a snag." |
return to message board, top of board |